1月14日，南模生物涨6.19%，截至发稿，报52.50元/股，成交5298.52万元，换手率1.36%，总市值40.93 亿元。南模生物股价已经连续5天上涨，区间累计涨幅13.26%。 截至发稿，吕俏累计任职时间1年13天，现任基金资产总规模5.06亿元，任职期间最佳基金回报 48.08%， 任职期间最差基金回报47.47%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 数据显示，天弘基金旗下1只基金位居南模生物十大流通股东。天弘医疗健康A（001558）三季度新进 十大流通股东，持有股数37.74万股，占流通股的比例为0.48%。根据测算，今日浮盈赚取约115.49万 元。连续5天上涨期间浮盈赚取218.53万元。 天弘医疗健康A（001558）成立日期2015年6月30日，最新规模2.63亿。今年以来收益14.09%，同类排 名261/8838；近一年收益55.87%，同类排名1806/8089；成立以来收益87.12%。 天弘医疗健康A（0 ...

Group 1 - Jiangsu Jicui Yaokang Biotechnology Co., Ltd. is located in Nanjing, Jiangsu Province, and was established on December 29, 2017, with its listing date on April 25, 2022 [1] - The company's main business involves the research, production, sales, and related technical services of laboratory animal mouse models, with the revenue composition being: commercial mouse model sales 55.36%, functional efficacy 23.46%, custom breeding 11.32%, model creation 7.06%, import-export agency and others 2.70%, and other (supplementary) 0.09% [1] Group 2 - Tianhong Medical Health A (001558) holds a significant position in its portfolio with a 8.88% net value proportion, being the second-largest heavy stock, having reduced its holdings by 645,200 shares to 2,486,000 shares [2] - The fund has achieved a return of 30.63% this year, ranking 3092 out of 8085 in its category, and a return of 28.76% over the past year, ranking 3069 out of 8085 [2] Group 3 - The fund manager of Tianhong Medical Health A is Lü Qiao, who has been in the position for 364 days, with the fund's total asset size at 506 million [3] - During Lü Qiao's tenure, the best fund return was 35.36%, while the worst was 34.83% [3]

Group 1 - The core viewpoint of the news is that Nanmo Biological has seen a stock price increase of 5.09%, reaching 48.35 yuan per share, with a total market capitalization of 3.77 billion yuan [1] - Nanmo Biological, established on September 20, 2000, specializes in the research, production, and sales of genetically modified animal models, with its main business revenue composition being: standardized models 48.34%, model technical services 21.92%, model breeding 19.50%, customized models 9.34%, and others 0.91% [1] Group 2 - Tianhong Fund's Tianhong Medical Health A (001558) has entered the top ten circulating shareholders of Nanmo Biological, holding 377,400 shares, which is 0.48% of the circulating shares, with an estimated floating profit of approximately 883,200 yuan [2] - Tianhong Medical Health A was established on June 30, 2015, with a latest scale of 263 million yuan, and has achieved a year-to-date return of 36.83% [2] Group 3 - The fund manager of Tianhong Medical Health A is Lü Qiao, who has a total fund asset scale of 506 million yuan, with the best fund return during the tenure being 41.15% and the worst being 40.68% [3]

Core Viewpoint - The announcement of fund manager Guo Xiangbo's departure from Tianhong Fund on October 14, 2025, due to personal reasons, marks a significant change in the management of Tianhong's healthcare-related funds [2][4]. Group 1: Fund Manager Departure - Guo Xiangbo has left his position as the fund manager for Tianhong Medical Innovation and Tianhong Selected Health, effective October 14, 2025 [2][4]. - Guo Xiangbo has been with Tianhong Fund for 11 years, having joined in February 2014, and previously served as the Director of Health Investment [4][5]. - During his tenure, Guo managed four funds, with the longest management period being for Tianhong Medical Health A, which achieved a return of 55.89% over 7 years [4][6]. Group 2: Fund Performance - The annualized returns for Tianhong Medical Innovation A and Tianhong Selected Health A are 2.45% and 7.27%, respectively, with both funds ranking in the top 50% of their peers [4][6]. - Tianhong Medical Health A, managed by Guo, has a return ranking of 163 out of 497 similar funds [4][6]. - Guo's managed assets were valued at 1.243 billion yuan before his departure, having peaked at over 2.1 billion yuan at the end of 2021 [5][6].